key: cord-1008089-17k06ti2 authors: Paradis, Sonia; Lockamy, Elizabeth; Cooper, Charles K.; Young, Stephen title: Clinical evaluation of the molecular-based BD SARS-CoV-2/flu for the BD MAX™ System date: 2021-08-20 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.104946 sha: 360e4eeebd267cbb5a83cb6bddab8017d52e9213 doc_id: 1008089 cord_uid: 17k06ti2 BACKGROUND: COVID-19 and influenza (Flu) share similar clinical symptoms. Therefore, differential detection of these three viruses during the respiratory virus seasons will be an important component for proper patient triage, management, and treatment. OBJECTIVES: Establish the diagnostic performance related to SARS-CoV-2 and Flu A/B detection for the BD SARS-CoV-2/Flu for BD MAX™ System (“MAX SARS-CoV-2/Flu”) multiplex assay. MATERIALS AND METHODS: Two hundred and thirty-five (235) retrospective nasopharyngeal specimens were obtained from external vendors. The BD BioGx SARS-CoV-2 Reagents for BD MAX™ System (“BioGx SARS-CoV-2”) and the Cepheid Xpert® Xpress Flu/RSV (“Xpert Flu/RSV”) were utilized as reference methods. RESULTS: By reference methods, 52 specimens were SARS-CoV-2-positive, 59 were Flu A-positive, and 60 were Flu B-positive. MAX SARS-CoV-2/Flu had positive percent agreement (PPA) and negative percent agreement (NPA) values for SARS-CoV-2 detection of 96.2% ([95%CI]:87.0-98.9) and 100% [95%CI:88.7-100], respectively; PPA values for Flu A and Flu B of 100% [95%CI:93.9-100] and 98.3% [95%CI:91.1-99.7], respectively, and NPA values for Flu A and Flu B of 98.9% [95%CI:94.0- 99.8] and 100% [95%CI:95.9-100], respectively. CONCLUSIONS: The MAX SARS-CoV-2/Flu assay met FDA-EUA performance criteria for SARS-CoV-2 (≥95% for PPA and NPA) and FDA clearance criteria for Flu A/B (PPA ≥90%; lower bound of the 95%CI ≥80%) and (NPA ≥95%; lower bound of the 95%CI ≥90%). Since the report of the first cluster of COVID-19 cases in December 2019, over 196 million COVID-19 cases and 4.19 million COVID-19-related deaths worldwide have been reported by the end of July, 2021, and the numbers continue to rise. [1, 2] In the U.S., more than 34.8 million COVID-19 cases and over 612,000 COVID-19 deaths have been recorded. [1] Although it seems that the 2020-2021 influenza season did not impact the health care systems, the 2019-2020 flu season resulted in over 38 million cases involving symptomatic illness and approximately 22,000 deaths in the U.S. [3] Each year, there are an estimated 1 billion cases of influenza globally, of which, 3-5 million are severe cases and 29,000-655,000 lead to influenza-related respiratory deaths. [4] Although as of now influenza activity is low in the U.S., [5] this virus has the potential of increasing the workload of healthcare workers already overwhelmed by As the society gradually reopens the social interactions in many places, the potential coincidence of both COVID-19 and influenza cases in high numbers during respiratory virus seasons is a significant concern. Therefore, differential detection of COVID-19 and influenza, will be an important component for proper patient triage, management, and treatment. Molecular diagnostics for the detection of SARS-CoV-2, including real-time polymerase chain reaction (RT-PCR) assays, have played an important role in the detection of SARS-CoV-2 and diagnosis of COVID-19 due to their high sensitivity. [6] Similarly, RT-PCR-based detection of Influenza A/B ("Flu A/B") virus nucleic acid has been established for a number of years and is commonly employed to establish an influenza diagnosis. [7] Due to the expected co-circulation with the potential co-infection of SARS-CoV-2 and Flu A/B, a multiplex RT-PCR assay, for detection all three targets, could help provide faster results and improve patient management and treatment. [8] This report describes the performance of the new BD SARS-CoV-2/Flu assay reagents for BD MAX™ System multiplex assay for detection of SARS-CoV-2 and Flu A/B. The comparator reference methods were the BD BioGx SARS-CoV-2 Reagents for BD MAX™ System and Cepheid Xpert ® Xpress Flu/RSV. The objective here was to determine the performance characteristics of the new multiplex BD SARS-CoV-2/Flu assay. Two hundred and thirty-five (235) nasopharyngeal specimens, either in Copan Universal Transport Medium (UTM ® ) or in BD Universal Viral Transport (UVT) system, were collected between November 30, 2019 and September 3, 2020 as part of standard of care (SOC). The samples were obtained from individuals with ages ranging from 1 year of age to ≥90 years of age and the residual transport media was stored at -65° C ~ -80°C (Table 1 and Flu A/B, respectively. [11] At the time this study was conducted there were no FDA cleared assays that detected all three targets.Therefore, two different assays, one EUA assay for testing SARS-CoV-2 and one cleared assay for testing Flu A/B and RSV were chosen as references. The BD BioGx SARS-CoV-2 assay was selected because of performance, meeting the FDA requirement of being a high sensitivity EUA RT-PCR assay which uses a chemical lysis step followed by solid phase extraction of nucleic acid and the availability of testing kits. (Table S1 ). The primary outcome measures for this study were positive and negative percent agreement (PPA and NPA, respectively) point estimates (with 95% confidence interval [95% CI] were calculated using the Wilson score method) for the MAX SARS-CoV-2/Flu assay, compared to each respective reference assay. The McNemar test was used for 2x2 classification to test the difference between paired proportions. The calculated difference is that of marginal proportions ([total proportion of SARS-CoV-2, Flu A, or Flu B positives] -[total proportion of positives (for each of the three causes) by clinical diagnosis]). A p-value <0.05 was utilized to distinguish significant differences (note here that a p-value >0.05 indicates only that disagreement between the two diagnostics methods is random). The Cohen's kappa coefficient was utilized to gauge the agreement between two raters (reference and test) to classify results into mutually exclusive categories. Κ=(P o -P e)/1-P e (<0, 0, and >0 indicating agreements worse than, no better or worse than, and better than that expected by chance). Acceptance criteria for the MAX SARS-CoV-2/Flu assay for US FDA-EUA authorization for SARS-CoV-2 was ≥95% for both PPA and NPA. [12] The PPA criteria for Flu A/B was ≥90% (lower bound of the 95%CI ≥80%) and the NPA criteria for Flu A/B was ≥95% (lower bound of the 95%CI ≥90%). Only compliant (no protocol deviations) and reportable results (no errors during specimen processing and a valid result obtained) for both MAX SARS-CoV-2/Flu and comparator assays were included in this analysis. This article was prepared according to standards for reporting of diagnostic accuracy studies (STARD) guidelines for diagnostic accuracy studies reporting. [13] Data Availability Data will be made publicly available upon publication and upon request for peer review. A total of 235 specimens were included in this study, from which, three were excluded due to (Table 3) . The PPA for the MAX SARS-CoV-2/Flu assay when compared to reference assays meet FDA- Different approaches are currently available for the detection of SARS-CoV-2 and Flu A/B for the diagnosis of both COVID-19 and influenza, respectively. [7, 15] Although culture-based assays were originally utilized to establish an influenza diagnosis, RT-PCR-based technology for detection of influenza currently represents the laboratory method of choice due to its relatively high analytic and clinical sensitivity, as well as short turn-around time. [16] Likewise, RT-PCRbased assays appear to have higher sensitivity for detection for SARS-CoV-2 compared to culture-based assays. [17] Rapid testing, such as immunochromatic techniques are used to detect viral antigen, have been developed for detection of both SARS-CoV-2 and Flu A/B. [6, 7] Although rapid tests carry advantages, such as decreased time-to-result and ease of implementation in decentralized health care settings, RT-PCR-based assays have increased analytical sensitivity compared to rapid tests. [7] Ultimately, multiple factors should be considered before determining which strategy should be employed. For example, hospitals and their associated laboratory partners, which have established a streamlined workflow and a relatively fast turn-around-time, can effectively employ RT-PCR-based assays-especially for patients admitted and managed according to their symptoms. This strategy carries the benefit of high sensitivity and the ability to rule out etiologic agents with a high degree of assurance. [19] [20] [21] [22] However, the lack of a gold standard for detecting SARS-CoV-2 precludes a firm conclusion according to discordant testing. If the coincidence of high rates of both COVID-19 and influenza cases occurs during a respiratory virus season, differential diagnosis for the appropriate therapeutic approach could be challenging. Although COVID-19 and influenza spread through a similar transmission mechanism and have overlapping symptomology, the isolation length and the therapeutic approach for COVID-19 patients and influenza patients are not uniform. [23] For example, COVID-19 seems to involve a longer time to symptom onset than influenza, and may cause more severe illness in vulnerable populations once symptoms develop. [24] The recommended isolation period after symptoms onset is a minimum of 4-5 days for influenza [25] whereas it is a minimum of 10 days for COVID-19, [26] impacting absenteeism and contact tracing. Also, the therapeutic approach for COVID-19 patients and influenza patients is not similar. The impact of anti-viral drug therapy, such as Tamiflu ® or Xoflusa, which have been used for influenza patients, [27] are not approved or their efficacy well-understood for patients with COVID-19. Therefore, safety concerns may preclude any potential efficacy. A similar concern exists for drugs such as remdesivir and corticosteroids, which have been used to treat COVID-19 patients, but are not approved for use in influenza patients, and may (for example, in the case of corticosteroids) have negative side effects in influenza patients. [23] Distinguishing the diagnosis of COVID-19 and influenza, therefore, will be an important component for proper patient triage, management, and treatment. This research was conducted by using materials obtained from pre-selected frozen remnants, received after routine care. A study involving prospective collection could result in better estimations of the positive and negative predictive values of the assay. The MAX SARS-CoV-2/Flu assays met US FDA-EUA acceptance criteria for SARS-CoV-2 and Flu A/B detection. Dual detection of the etiologic agents causing COVID-19 and influenza will allow differentiation for those exhibiting common symptoms between the two diseases. This assay should help optimize patient management by decreasing the time and resources required for dual testing. Ultimately, the dual detection method should facilitate an informed decision by physicians on the appropriate treatment for patients exhibiting similar symptoms between the two diseases. [27] U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) Information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamifluoseltamivir-phosphate-information. 2018. Coronavirus Resource Center. Mortality Analyses Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Estimated Influenza Illness, Medical Visits, Hospitalizations, and Deaths in the United States-2019-2020 Influenza Season Global influenza strategy 2019-2030. Geneva: World Health Organization Cataloguing-in-Publication (CIP) data World Helath Organization. Influenza Update -383 Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2 Current Approaches for Diagnosis of Influenza Virus Infections in Humans What Happens When COVID-19 Collides With Flu Season? Clinical and experimental factors that affect the reported performance characteristics of rapid testing for SARS-CoV-2 Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes Food and Drug Administration. BD SARS-CoV-2/Flu for BD MAX System -Letter of Authorization Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization for Medical Devices An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays Influenza (Flu) Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture BD SARS-CoV-2 Reagents for BD MAX™ System CoV-2/Flu for BD MAX™ System BD BioGX SARS-CoV-2 Reagents for BD MAX™ System Food and Drug Administration. SARS-CoV-2 Reference Panel comparative Data COVID-19 Vaccine: A comprehensive status report Stay at home when you are sick Options to reduce quarantine for contacts of persons with SARS-CoV-2 infection using symptom monitoring and diagnostic testing Reference method was the BioGx SARS-CoV-2 RT-PCR assay. significant difference (via McNemar's test on paired proportions was not observed for MAX SARS-CoV-2/Flu for detection of SARS-CoV-2 We thank Karen Eckert and Karen Yanson (Becton, Dickinson and Company, BD Life Sciences -Integrated Diagnostic Solutions) for their input on the study logistics and content of this manuscript and editorial assistance. We also thank Yu-Chih Lin and Devin Gary for the editorial assistance. We thank Stanley Chao, Aojun Li, and Yongqiang Zhang (Becton, Dickinson and Company, BD Life Sciences -Integrated Diagnostic Solutions) for statistical support. The individuals acknowledged here have no additional funding or additional compensation to disclose. We are grateful to the study participants who allowed this work to be performed. The authors disclose the following conflicts of interest: SP, EL, and CKC are employees of Becton, Dickinson and Company; SY, None. One specimen corresponded to a Ct value for the N1 result = 39.5 and an N2 result = negative. One specimen corresponded to a N1 result = negative and a Ct value for the N2 result = 38.8. Discrepancy testing with the BioFire SARS-CoV-2 assay was negative (agreement with MAX) for both specimens. b One specimen (not shown here) was positive by MAX (Ct value = 38.8) and negative by Xpert Flu.Discrepancy testing with the Liat Flu assay was positive (agreement with MAX SARS-CoV-2/Flu). c Ct value for the Xpert Flu result = 37.8. Discrepancy testing with the Liat Flu assay was positive (agreement with Xpert Flu).